Evidence map›Paper›PMID 34711063›Full record

ArticleJournal of diabetes science and technology2022

More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data.

Richard M Bergenstal, Gregg D Simonson, Lutz Heinemann

Registry-linked trialAbstract readEditorial
In one paragraph

Article in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07325201 (Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07325201 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report

TypeinterventionalSponsorHealthPartners InstituteRan2026 to 2030Enrolled80ConditionsType 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic KetoacidosisArmsSotagliflozin initiation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Roadmap to the Effective Use of Continuous Glucose Monitoring: Innovation, Investigation, and Implementation.Diabetes spectrum : a publication of the American Diabetes Association · 2023
    Article
  6. Diabetes Technology Meeting 2021.Journal of diabetes science and technology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Richard M BergenstalInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA.ORCID 0000-0002-9050-5584
Gregg D SimonsonInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA.ORCID 0000-0001-5561-2547
Lutz HeinemannScience-Consulting in Diabetes GmbH, Kaarst, Germany.ORCID 0000-0003-2493-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blood Glucose Self-MonitoringDiabetes Mellitus, Type 1Blood GlucoseHumansReference StandardsBlood GlucoseAID systemsblood glucose meterCGMdiabetes devicesmedical products

Identifiers

PMID34711063
PMCPMC8875060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.